Full-Time

Senior Principal Software Developer

Deadline 7/10/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

New Castle, DE, USA

Hybrid

Three days on-site per week required.

Category
Software Engineering (1)
Required Skills
Datadog
Microsoft Azure
React.js
Git
Machine Learning
Docker
TypeScript
.NET
Microservices
C#
AWS
JIRA
REST APIs
Confluence
DevOps
AngularJS
HTML/CSS
Google Cloud Platform
Requirements
  • Bachelor’s Degree preferred, or equivalent combination of education, training, and experience
  • 12+ years of experience in software engineering, preferably in a regulated development environment
  • 3+ years of technical leadership experience, guiding software teams through architecture, design, and delivery of complex software solutions
  • 5+ years of proven experience designing and architecting SaaS solutions, including multi-tenant architecture, CI/CD pipelines, and cloud-native services with major cloud service providers such as AWS, Azure, or Google
  • Strong experience with C#, .NET Core, and object-oriented design
  • Front-end development expertise using React or Angular with TypeScript
  • Proficiency in web technologies: HTML, CSS, REST APIs
  • Hands-on experience with AWS or Azure Cloud, Docker containers, and microservices
  • Familiarity with development tools such as JIRA, Visual Studio, VS Code, GitHub, YAML, Confluence, and Datadog
  • Experience integrating AI/ML models into production systems is a strong plus
  • Strong understanding of software security best practices and implementation
Responsibilities
  • Lead the architecture and design of a new SaaS platform with integrated AI/ML capabilities
  • Define and drive the technical roadmap, ensuring alignment with business goals and scalability requirements
  • Research, design, develop, and maintain applications, user interfaces, data analysis tools, and instrument control software for thermal analysis, rheological, and calorimetric instruments
  • Evaluate system specifications and translate system requirements into detailed technical designs
  • Provide architectural guidance and mentorship to engineering teams across the full development lifecycle
  • Collaborate with cross-functional teams to ensure seamless integration of AI models and services into the SaaS platform
  • Ensure software quality through code reviews, automated testing, and adherence to SOLID principles and secure coding practices
  • Contribute to the application architecture with a focus on scalability, maintainability, security, and performance
  • Support current programs, including performance tuning, troubleshooting, and enhancements
  • Provide technical support to internal and external users as needed
  • Participate in agile ceremonies and collaborate with global teams
  • Share knowledge through demos, documentation, and mentoring
  • Demonstrate continuous technical improvement and thought leadership
Desired Qualifications
  • Experience in analytical or medical device domains
  • Knowledge of TCP/IP sockets and RS232-serial communications
  • Experience with Azure DevOps, GitHub, BDD (Gherkin & SpecFlow), and continuous delivery pipelines
  • Ability to create roadmaps, manage risks, and communicate progress to stakeholders
  • Experience bridging technical and non-technical teams
  • Background in cross-functional product development involving hardware and software components

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
  • Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
  • China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.

What critics are saying

  • Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
  • $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
  • BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.

What makes Waters Corporation unique

  • BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
  • omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
  • ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.